In cancer cells, the absence of IGF1R-linked glycans at Asn913 compromised its membranous localization, being associated with insensitivity to figitumumab (a humanized anti-IGF1R antibody), suggesting that changes in the pattern of the expression of N-glycans attached to the growth receptor modulate the sensitivity to target therapy in cancer cells [56]. This evidence concerns the gene IGF1R and cancer.